Furosemide Injection Small Volume Parenteral antihypertensive
Product : Furosemide Injection
Specification : 20mg/2ml
Standard : BP, USP
Packing : 10 x 10amps/box
A benzoic-sulfonamide-furan. It is a diuretic with fast onset and
short duration that is used for edema and chronic renal
Indications and Dosages :
➤➤To reduce edema caused by cirrhosis, heart failure, and renal
disease, including nephrotic syndrome
oral solution, tablets
Adults. 20 to 80 mg as a single dose, increased by 20 to 40 mg every 6 to
8 hr until desired response occurs. Maximum: 600 mg daily.
Children. 2 mg/kg as a single dose, increased by 1 to 2 mg/kg every 6 to 8
hr until desired response occurs. Maximum: 6 mg/kg/dose.
i.v. infusion, i.v. or i.m. injection
Adults. 20 to 40 mg as a single dose, increased by 20 mg every 2 hr until
desired response occurs.
Children. 1 mg/kg as a single dose, increased by 1 mg/kg every 2 hr until
desired response occurs. Maximum: 6 mg/kg/dose.
dosage adjustment Initial single dose limited to 20 mg for elderly patients.
➤➤To manage mild to moderate hypertension, as adjunct to treat acute
pulmonary edema and hypertensive crisis
oral solution, tablets
Adults. Initial: 40 mg twice daily, adjusted until desired response occurs. Maximum: 600 mg daily.
i.v. infusion or injection
Adults with normal renal function. 40 to 80 mg as a single dose over several minutes.
Adults with acute renal failure or pulmonary edema. 100 to 200 mg as a single dose over several minutes.
dosage adjustment For patients with acute pulmonary edema without hypertensive
crisis, dosage reduced to 40 mg followed by 80 mg 1 hr later if
therapeutic response doesn’t occur.
Route Onset Peak Duration
P.O. 20–60 min 1–2 hr 6–8 hr
I.V. 5 min In 30 min 2 hr
I.M. 30 min Unknown 2 hr
Furosemide, a sulfonamide-type loop diuretic structurally related
to bumetanide, is used to manage hypertension and edema associated
with congestive heart failure, cirrhosis, and renal disease,
including the nephrotic syndrome.
Mechanism of action :
Furosemide, a loop diuretic, inhibits water reabsorption in the
nephron by blocking the sodium-potassium-chloride cotransporter
(NKCC2) in the thick ascending limb of the loop of Henle. This is
achieved through competitive inhibition at the chloride binding
site on the cotransporter, thus preventing the transport of sodium
from the lumen of the loop of Henle into the basolateral
interstitium. Consequently, the lumen becomes more hypertonic while
the interstitium becomes less hypertonic, which in turn diminishes
the osmotic gradient for water reabsorption throughout the nephron.
Because the thick ascending limb is responsible for 25% of sodium
reabsorption in the nephron, furosemide is a very potent diuretic.